PDS appoints Paul Butler and Martin Slade
pharmafile | December 22, 2009 | Appointment | Manufacturing and Production | PDS, Pharmaceutical Development Services, appointment, manufacturing and production
Pharmaceutical Development Services Ltd (PDS) has expanded its API (Active Pharmaceutical Ingredient) auditing capability, appointing two new associates.
Paul Butler and Martin Slade join the pharmaceutical consultancy and both have extensive CVs with particular expertise in API auditing in Europe, India and China.
PDS managing director Michael Gamlen said: “Having Martin and Paul available to add to the PDS body of expertise represents a considerable opportunity and I had no hesitation in bringing them onto the team.
“We are finding that API is a very hot topic at the moment. Some pharmaceutical sourcing, particularly from Asia, is proving of variable quality, leading to increased regulatory scrutiny. API Supplier Auditing is a key element of the international effort to maintain pharmaceutical supply chain integrity and avoid problems with counterfeit products and adulterated APIs.”
Based in Nottingham and Beckenham in the UK and South Carolina in the US, PDS plans further expansion in the New Year.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …